Herborium Group 2014 Third Quarter Sales Grows 105% Over the Same Quarter in 2013
Fort Lee, N.J. October 6, 2014 Herborium® Group, Inc. (OTC Pink: HBRM), www.Herborium.com, a Botanical Therapeutics® Company and the provider of unique all botanical medicines (Botanical Therapeutics®) announced today that its Third Quarter sales for 2014 grew 105% over the same quarter in 2013
In addition, the company cited the following results that marked a successful completion of the Third Quarter.
- The Company’s gross profit in 3rd Quarter 2014 increased 80% over the same period in 2013
- The loss from operations in Third Quarter of 2014 was cut in half compared with the Third Quarter of 2013
- Sales for the first three Quarters of 2014 are 31% higher than ENTIRE 2013 annual sales
- Herborium’s Facebook “likes” approached 10,000 which represents another 10% increase compared with just the previous quarter Q2 2014.
“The Company’s growth continues and we look forward to maintaining our successful path to accelerating time to market and profitability, and in the development of novel natural medicines-Botanical Therapeutics®”. Commented Dr. Agnes P. Olszewski, CEO and Chairwoman of Herborium Group.
About Herborium Group, Inc.
Herborium Group, Inc., a botanical therapeutics® company that develops, license and markets proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. Herborium has secured a pipeline of botanical ingredients based products in the areas of dermatological needs, wellness and energy, prostate health, women’s health and selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, diabetes, surgical procedures, and other problems. Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce. For more information, please visit www.herborium.com, and www.acnease.com.
Safe Harbor Statement: This release contains forward-looking statements with respect to the results of operations and business of Herborium Group, Inc., which involves risks and uncertainties. The Company's actual future results could materially differ from those discussed. The Company intends that such statements about the Company's future expectations, including future revenues and earnings, and all other forward looking statements be subject to the "Safe Harbors" provision of the Private Securities Litigation Reform Act of 1995.
Information: Herborium Group, Inc.